Business Wire

Momcozy Introduces the Revolutionary M5 All-in-one Hands-free Breast Pump - Empowering Busy Moms with the Ultimate Maternity Solution

8.6.2023 23:00:00 EEST | Business Wire | Press release

Share

Momcozy, the esteemed maternity and baby brand favored by over two million moms worldwide, proudly unveils the revolutionary M5 all-in-one hands-free breast pump. Designed to provide the ultimate pumping experience for busy breastfeeding moms, this cutting-edge device showcases Momcozy's commitment to meeting the needs of mothers worldwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230608005079/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

M5 All-in-one Handsfree Breast Pump (Graphic: Business Wire)

Renowned for its position as a leader in the North American electric breast pump market, Momcozy distinguishes itself yet again with the M5 all-in-one hands-free breast pump. Driven by a user research team that believes in "cozy designs born from love" and strives to cater to customer needs, Momcozy has conducted extensive interviews with thousands of mothers over the past two years.

The team's latest findings highlight "comfort" as the most frequently mentioned requirement among breastfeeding moms, which has significantly influenced the design of the M5 wearable breast pump.

The M5 all-in-one handsfree breast pump stands apart with its unique baby mouth-shaped design, featuring a soft silicone flange set at a precise angle of 105 degrees. By closely imitating the natural suckling position of a baby, it minimizes the risk of nipple pain and discomfort, ensuring a comfortable pumping experience.

Setting new standards in convenience, the M5 all-in-one hands-free breast pump introduces an exclusive vibration suction mode that stimulates milk flow and enhances the overall pumping process. Combining the power of suction and vibration, this feature allows for swift and efficient milk extraction, enabling moms to pump quickly and comfortably.

Additionally, its discreet size enables moms to use it inconspicuously, without drawing attention or hindering their activities, thereby ensuring productivity throughout the day.

To complement its functionality, the M5 all-in-one hands-free breast pump comes with a trendy hard-shell storage bag to cater to the needs of busy moms who are always on the move. Delighted customers have praised the bag for its excellent protection of the breast pumps and parts. The M5 all-in-one hands-free breast pump set includes two breast pumps and all the necessary accessories, including different sizes of flanges, ensuring moms can commence using the breast pump as soon as they receive it. As one satisfied mom noted, "the set offers everything you need altogether."

In a recent survey among women currently or recently using a breast pump, portability, low weight, fast milk extraction, and comfort were rated as crucial factors, with low noise and discreetness also important to younger mothers. By addressing these needs, Momcozy's wearable breast pump has consistently ranked as the top seller. Momcozy places great importance on research and development, guaranteeing that its products are of the highest quality and perfectly aligned with the needs of breastfeeding mothers. That’s why the M5 all-in-one hands-free breast pump emerges as the ultimate solution for busy moms seeking to provide their babies with breast milk while effectively managing their work-life balance.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Marketing Dept.
Joanna Tsai
pr@momcozy.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye